HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older who have HIV-1 and have received at least one dose of the long-acting injectable cabotegravir/rilpivirine (a type of HIV treatment given as an injection) between September 1, 2021, and March 31, 2024.
Who may not be able to join:
- No specific exclusion criteria were listed in the official information provided (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stéphane De Wit, MD/PhD, Belgian Research on AIDS & HIV Consortium
Phone: +32 2 535 4130
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate participant perception of, and satisfaction with, LAI CAB/RPV for the treatment of HIV
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.